▼Vitrakvi

Congresos 2024

En esta página podrá descargarse la información más relevante de Larotrectinib presentada en los congresos de 2024.

ASCO 2024

Outcomes of Larotrectinib compared with real-world data from non-TRK inhibitor therapies

Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study. JCO

, 3105-3105(2024). DOI:10.1200/JCO.2024.42.16_suppl.3105

Larotrectinib in TRK fusion Thyroid Carcinoma

Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). JCO

, 6095-6095(2024). DOI:10.1200/JCO.2024.42.16_suppl.6095

Larotrectinib in TRK fusion Lung Cancer

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. JCO

, 9056-9056(2023). DOI:10.1200/JCO.2023.41.16_suppl.9056

Larotrectinib in TRK fusion GI Cancer

Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer. JCO

, 109-109(2024). DOI:10.1200/JCO.2024.42.3_suppl.109

Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer: an updated analysis